Neurocrine Biosciences (NASDAQ:NBIX – Free Report) had its target price raised by Mizuho from $112.00 to $113.00 in a report released on Monday morning, Briefing.com reports. They currently have a neutral rating on the stock. A number of other brokerages have also weighed in on NBIX. SVB Leerink upgraded shares of Neurocrine Biosciences from a […]
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Q2 2023 Earnings Call Transcript August 1, 2023 Neurocrine Biosciences, Inc. misses on earnings expectations. Reported EPS is $-0.18 EPS, expectations were $0.77. Operator: Good day, everyone, and welcome to today’s Neurocrine Biosciences Reports Second Quarter Results. [Operator Instructions] It is now my pleasure to turn today’s program over to Todd […]
/PRNewswire/ Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the Goldman Sachs 44th Annual Global Healthcare Conference on Thursday, June 15,.
SAN DIEGO, June 8, 2023 /PRNewswire/ Neurocrine Biosciences, Inc. will present at the Goldman Sachs 44th Annual Global Healthcare Conference on Thursday, June 15, 2023 at 8:00 a.m. Pacific Time . | June 9, 2023
Guggenheim upgraded shares of Neurocrine Biosciences (NASDAQ:NBIX – Get Rating) from a neutral rating to a buy rating in a research note released on Thursday, The Fly reports. The brokerage currently has $145.00 price target on the stock. Several other equities research analysts have also issued reports on NBIX. Canaccord Genuity Group raised shares of […]